查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
糖尿病視網膜病變市場 - 成長，未來展望，競爭分析，2022年～2030年
市場調查報告書
商品編碼
1167504

糖尿病視網膜病變市場 - 成長，未來展望，競爭分析，2022年～2030年

Diabetic Retinopathy Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 119 Pages | 商品交期: 最快1-2個工作天內

價格

本報告提供全球糖尿病視網膜病變市場相關調查，提供市場概要，以及各類型設備，藥物各類型，各用途，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

第2章 摘要整理

第3章 糖尿病視網膜病變市場:競爭分析

  • 主要的糖尿病視網膜病變市場供應商的市場定位
  • 糖尿病視網膜病變市場供應商採用的策略
  • 主要的產業策略
  • 階層分析2021年對2030年

第4章 糖尿病視網膜病變市場:常量分析和市場動態

  • 簡介
  • 全球糖尿病視網膜病變的市場價值，2020年～2030年，(100萬美元)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要的機會
  • 促進因素與阻礙因素的影響分析
  • Seesaw分析

第5章 糖尿病視網膜病變市場:各類型設備，2020年～2030年，(100萬美元)

  • 市場概要
  • 成長和收益分析:2021年對2030年
  • 市場區隔
    • 焦點雷射治療
    • 散亂雷射治療
    • 玻璃體切除設備

第6章 糖尿病視網膜病變市場:藥物各類型，2020年～2030年，(100萬美元)

  • 市場概要
  • 成長和收益分析:2021年對2030年
  • 市場區隔
    • 阿柏西普 (Eylea)
    • 貝伐珠單抗（阿瓦斯汀）
    • 氟輕鬆 (Iluvien)
    • 雷珠單抗（Lucentis）
    • 曲安奈德注射液

第7章 北美的糖尿病視網膜病變市場，2020年～2030年，(100萬美元)

第8章 英國及EU的糖尿病視網膜病變市場，2020年～2030年，(100萬美元)

第9章 亞太地區的糖尿病視網膜病變市場，2020年～2030年，(100萬美元)

第10章 南美的糖尿病視網膜病變市場，2020年～2030年，(100萬美元)

第11章 中東·非洲的糖尿病視網膜病變市場，2020年～2030年，(100萬美元)

第12章 企業簡介

  • Alimera Sciences, Inc
  • Pfizer
  • Genentech USA, Inc.
  • Sandoz Inc.
  • Bayer Pharma AG
  • Regeneron Pharmaceuticals Inc.
  • Sirnaomics
  • Iridex Corporation
  • Lumenis
  • Valon Lasers OY
  • 其他
Product Code: 136948-08-22

Diabetic retinopathy is among the leading causes of legal blindness among the working-age adults worldwide. Anticipated increase in prevalence of diabetes prevalence indicates that diabetic retinopathy will continue to the prevalence of vision loss in the future. Diabetes and diabetes related complications carry heavy economic burden. Estimates also suggest that diabetic retinopathy alone contributes 10% to 42% of direct medical costs, whereas the indirect costs could be much higher. Surgical treatments have been preferred for a long time for diabetic retinopathy treatment at severe stages. Several pharmacological treatments are introduced and many are in development for treating this complication. This report studies the global and regional markets for various diabetic retinopathy treatments currently available.

For the purpose of this study, the global diabetic retinopathy market is assessed for diabetic retinopathy treatment devices and drugs. The devices market is categorized into focal laser treatment, scatter laser treatment and vitrectomy devices. the diabetic retinopathy treatment drugs is studied for aflibercept (Eylea), bevacizumab (Avastin), fluocinolone acetonide (Iluvien), ranibizumab (Lucentis) and triamcinolone acetonide. Global market size and forecast for the mentioned segments for the period 2020-2030 along with corresponding CAGRs for the forecast period 2022-2030 are included in this section.

The market size and forecast for the period 2020-2030 along with the CAGRs for the period 2022-2030 for the mentioned segments are also presented in this study.

Qualitative information sets such as market dynamics (drivers, challenges, future prospects) and market inclination insights are provided in this market assessment report. Tools such as competition assessment and attractive investment proposition are also included in this study for studying the global market competition. The report concludes with company profiles section that highlights key information about the major market players operating in the global diabetic retinopathy market.

Devices Segmentation Investigation

Diabetic retinopathy has been treated through devices for a long time, and even after advent of advanced drugs, it considered as the most preferred treatment regime. Laser treatment is often preferred for treating the formation of new blood vessels in the advanced stages of diabetic retinopathy. Laser treatment is often preferred because the new blood vessels formed are often very weak and laser treatment successfully stabilizes the risk of vision loss, though not improve the damaged vision. Quick turnaround time and immediate recovery and effect are the prime factors that lead to high preference for laser treatments. Alike laser treatment, vitrectomy does not cure diabetic retinopathy, but is opted as an effective management mode. Despite the proven efficacy of vitrectomy in diabetic retinopathy management, late diagnosis of condition holds back the growth of this market.

In cases of diabetic macular edema, which can occur at any stage of diabetic retinopathy injections of anti-VEGF agents are administered to patients directly into the eye to prevent formation of new blood vessels at the back of the eye. Chief medicines used are ranibizumab and aflibercept. These drugs not only efficiently manage diabetic macular edema, but also are also instrumental in vision improvement. Other intravitreal treatments for diabetic macular edema are Fluocinolone intravitreal implant (Iluvien), Bevacizumab (Avastin) and Triamcinolone acetonide injections. Iluvien form Alimera Sciences, Inc. received FDA approval in 2014 for treating diabetic macular edema in patients who have been previously treated with corticosteroids and did not witness significant rise in intraocular pressure. The drug is also been under trial for treatment of dry age-related macular degeneration.

Gradual rise in prevalence of diabetes and escalating diagnosis of diabetes related complications, favorable reimbursement policies and early introduction of breakthrough treatment modalities are the chief drivers that have allowed North America a dominant position in the diabetic retinopathy market. Extensive penetration of patented drugs such as Lucentis, Eylea, Iluvien and Avastin in the U.S. market has contributed to the clear leadership of North America in this area. Followed by North America, Europe is the second largest market for diabetic retinopathy due to high awareness in healthcare professionals and patients about effective management of diabetes related compilations and swift adoption of new treatments. Countries such as India and China while witnessing phenomenal growth in diabetes prevalence and improving rates of diagnosis will make Asia-Pacific the fastest progressing regional market for diabetic retinopathy treatment. Other factors contributing to the growth of this regional market are growth in healthcare expenditure, improving disposable income and development of healthcare infrastructure to facilitate medical tourism.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Diabetic Retinopathy market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Diabetic Retinopathy market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Device Type

Focal Laser Treatment

Scatter Laser Treatment

Vitrectomy Devices

Drug Type

Aflibercept (Eylea)

Bevacizumab (Avastin)

Fluocinolone Acetonide (Iluvien)

Ranibizumab (Lucentis)

Triamcinolone Acetonide Injection

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Diabetic Retinopathy market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Diabetic Retinopathy market?

Which is the largest regional market for Diabetic Retinopathy market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Diabetic Retinopathy market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Diabetic Retinopathy market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Diabetic Retinopathy Market
  • 2.2. Global Diabetic Retinopathy Market, By Device Type, 2021 (US$ Million)
  • 2.3. Global Diabetic Retinopathy Market, By Drug Type, 2021 (US$ Million)
  • 2.4. Global Diabetic Retinopathy Market, By Geography, 2021 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2021

3. Diabetic Retinopathy Market: Competitive Analysis

  • 3.1. Market Positioning of Key Diabetic Retinopathy Market Vendors
  • 3.2. Strategies Adopted by Diabetic Retinopathy Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Diabetic Retinopathy Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Diabetic Retinopathy Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Focal Laser Treatment
    • 5.3.2. Scatter Laser Treatment
    • 5.3.3. Vitrectomy Devices

6. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 6.3. Market Segmentation
    • 6.3.1. Aflibercept (Eylea)
    • 6.3.2. Bevacizumab (Avastin)
    • 6.3.3. Fluocinolone Acetonide (Iluvien)
    • 6.3.4. Ranibizumab (Lucentis)
    • 6.3.5. Triamcinolone Acetonide Injection

7. North America Diabetic Retinopathy Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
  • 7.3. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
  • 7.4.Diabetic Retinopathy Market: By Region, 2020-2030, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 7.4.1.1.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 7.4.1.2.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 7.4.1.3.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)

8. UK and European Union Diabetic Retinopathy Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
  • 8.3. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
  • 8.4.Diabetic Retinopathy Market: By Region, 2020-2030, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 8.4.1.1.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 8.4.1.2.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 8.4.1.3.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 8.4.1.4.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 8.4.1.5.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 8.4.1.6.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)

9. Asia Pacific Diabetic Retinopathy Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
  • 9.3. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
  • 9.4.Diabetic Retinopathy Market: By Region, 2020-2030, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 9.4.1.1.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 9.4.1.2.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 9.4.1.3.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 9.4.1.4.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 9.4.1.5.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 9.4.1.6.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)

10. Latin America Diabetic Retinopathy Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
  • 10.3. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
  • 10.4.Diabetic Retinopathy Market: By Region, 2020-2030, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 10.4.1.1.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 10.4.1.2.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 10.4.1.3.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)

11. Middle East and Africa Diabetic Retinopathy Market, 2020-2030, USD (Million)

  • 11.1. Market Overview
  • 11.2. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
  • 11.3. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
  • 11.4.Diabetic Retinopathy Market: By Region, 2020-2030, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 11.4.1.1.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 11.4.1.2.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Diabetic Retinopathy Market: By Device Type, 2020-2030, USD (Million)
        • 11.4.1.3.1. Diabetic Retinopathy Market: By Drug Type, 2020-2030, USD (Million)

12. Company Profile

  • 12.1. Alimera Sciences, Inc
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Pfizer
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Genentech USA, Inc.
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Sandoz Inc.
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Bayer Pharma AG
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Regeneron Pharmaceuticals Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Sirnaomics
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Iridex Corporation
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Lumenis
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Valon Lasers OY
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Other Notable Players
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 2 Global Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 3 North America Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 4 North America Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 5 U.S. Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 6 U.S. Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 7 Canada Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 8 Canada Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 9 Rest of North America Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 10 Rest of North America Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 11 UK and European Union Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 12 UK and European Union Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 13 UK Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 14 UK Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 15 Germany Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 16 Germany Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 17 Spain Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 18 Spain Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 19 Italy Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 20 Italy Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 21 France Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 22 France Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 23 Rest of Europe Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 24 Rest of Europe Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 25 Asia Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 26 Asia Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 27 China Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 28 China Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 29 Japan Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 30 Japan Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 31 India Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 32 India Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 33 Australia Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 34 Australia Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 35 South Korea Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 36 South Korea Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 37 Latin America Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 38 Latin America Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 39 Brazil Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 40 Brazil Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 41 Mexico Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 42 Mexico Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 43 Rest of Latin America Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 44 Rest of Latin America Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 45 Middle East and Africa Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 46 Middle East and Africa Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 47 GCC Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 48 GCC Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 49 Africa Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 50 Africa Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Diabetic Retinopathy Market By Device Type, 2020-2030, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Diabetic Retinopathy Market By Drug Type, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Diabetic Retinopathy Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Diabetic Retinopathy Market: Quality Assurance
  • FIG. 5 Global Diabetic Retinopathy Market, By Device Type, 2021
  • FIG. 6 Global Diabetic Retinopathy Market, By Drug Type, 2021
  • FIG. 7 Global Diabetic Retinopathy Market, By Geography, 2021
  • FIG. 8 Market Geographical Opportunity Matrix - Global Diabetic Retinopathy Market, 2021
  • FIG. 9 Market Positioning of Key Diabetic Retinopathy Market Players, 2021
  • FIG. 10 Global Diabetic Retinopathy Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 11 Global Diabetic Retinopathy Market, By Device Type, 2021 Vs 2030, %
  • FIG. 12 Global Diabetic Retinopathy Market, By Drug Type, 2021 Vs 2030, %
  • FIG. 13 U.S. Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 14 Canada Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 15 Rest of North America Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 16 UK Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 17 Germany Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 18 Spain Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 19 Italy Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 20 France Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 21 Rest of Europe Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 22 China Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 23 Japan Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 24 India Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 25 Australia Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 26 South Korea Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Asia Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 28 Brazil Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 29 Mexico Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 30 Rest of Latin America Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 31 GCC Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 32 Africa Diabetic Retinopathy Market (US$ Million), 2020 - 2030
  • FIG. 33 Rest of Middle East and Africa Diabetic Retinopathy Market (US$ Million), 2020 - 2030